Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention

Inclusion Criteria: * 55 years or older * Non-demented: Montreal Cognitive Assessment \> 26 and Clinical Dementia Rating = 0 * Diagnosis of Essential Hypertension with systolic 90-160 mm Hg and diastolic 60-90 mm Hg * Stable dose of antihypertensive medication 4 month prior to study enrollment * Stable dose of lipid lowering medication - dose must be stable for 4 months prior to study enrollment * Low Omega-3 fatty acid Status: Omega-3 index, \< 4% of total fatty acid of combined docosahexaenoic acid and eicosapentanoic acid * Geriatric Depression Scale \< 5 * General health status that will not interfere with the participant's ability to complete the study. * Screening laboratory values within normal limits or, if abnormal, deemed clinically insignificant by the investigator * Sufficient English language skills to complete all testing Exclusion Criteria: * Alzheimer's, Dementia or other neurodegenerative disease. * Health conditions such as cancer diagnosed \< 5 years prior to enrollment (prostate cancer gleason grade \< 3 and non metastatic skin cancers are acceptable), liver disease, history of ventricular fibrillation or ventricular tachycardia, major psychiatric disorder, central nervous system diseases (e.g. brain tumor, seizure disorder) * Insulin dependent diabetes or uncontrolled diabetes (diabetes controlled on medications other than insulin are acceptable) * Fish intake of one 6 ounce serving \> once a week less than 4 months prior to enrollment * Omega-3 fatty acid supplement intake (e.g. fish oil capsules, cod liver oil) less than 4 months prior to enrollment * Lipoic Acid supplementation less than 1 month prior to enrollment * Taking systemic corticosteroids, neuroleptics, antiparkinsonian agents, and/or narcotic analgesics. Low dose sinemet and dopamine agonist taken once a day for restless leg syndrome is not an exclusion. * Contraindications to MRI, including: subjects with intrathecal pumps, stimulators, pacemakers, aneurysm clips, non-removable hearing aids, or metal fragments in the eyes. Other exclusion criteria include the inability to lie flat on the back for 40 minutes at a time or a self-reported history of claustrophobia. Subjects with a history of hip replacement and those with well-documented, verifiable, MRI-safe cardiac stents will not be excluded from the study. * Enrollment in another treatment study